History of primary immunodeficiency diseases

Ochs, Hans D.; Hitzig, W. H.

doi:10.1097/aci.0b013e32835923a6

Cited by 49 publications

(32 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In 1950, Eduard Glanzmann and Paul Riniker found that Candida albicans infections are associated with an absence of lymphocytes. 1 Two Swiss groups from Bern and Zurich (Hassig Cottier, R.Tobler and Walter Hitzig) discovered similar patients in 1958 and recognized it to be an immunodeficiency. This condition that was initially coined as Swiss type agammaglobulinemia was renamed as severe combined immunodeficiency (SCID) by world health organization (WHO) in 1970.…”

Section: Historymentioning

confidence: 99%

“…This condition that was initially coined as Swiss type agammaglobulinemia was renamed as severe combined immunodeficiency (SCID) by world health organization (WHO) in 1970. 1 In 1954, Robert Good discovered a fatal granulomatous disease that is now known as chronic granulomatous disease (CGD). 1 Over the last 65 years, the field of PIDs has advanced exceedingly.…”

Section: Historymentioning

confidence: 99%

“…1 In 1954, Robert Good discovered a fatal granulomatous disease that is now known as chronic granulomatous disease (CGD). 1 Over the last 65 years, the field of PIDs has advanced exceedingly. With the advent of cutting-edge genetic technology, more than 240 PIDs have been discovered and the number continues to increase.…”

Section: Historymentioning

confidence: 99%

See 2 more Smart Citations

Overview of Immunodeficiency Disorders

Raje

Dinakar

2015

Immunology and Allergy Clinics of North America

101

View full text Add to dashboard Cite

Synopsis The spectrum of primary immunodeficiency disorders (PID) is expanding. It includes typical disorders that primarily present with defective immunity as well as disorders that predominantly involve other systems and exhibit few features of impaired immunity. The rapidly growing list of new immunodeficiency disorders and treatment modalities makes it imperative for the provider to stay abreast of the latest and best management strategies. We present a brief overview of recent clinical advances in the field of PIDs.

show abstract

Section: Historymentioning

confidence: 99%

Section: Historymentioning

confidence: 99%

See 1 more Smart Citation

Overview of Immunodeficiency Disorders

Raje

Dinakar

2015

Immunology and Allergy Clinics of North America

101

View full text Add to dashboard Cite

show abstract

“…[1][2][3][4] Patients with primary immunodeficiency disorders are more likely to experience recurrent, serious, and unusual infections and have a tendency to develop a wide range of complications. [5][6][7] The true incidence and prevalence of primary immunodeficiency disorders are not known.…”

Section: Introductionmentioning

confidence: 99%

Sinopulmonary Complications in Subjects With Primary Immunodeficiency

Owayed

Al‐Herz

2016

Respir Care

View full text Add to dashboard Cite

BACKGROUND: The aim of this work was to describe the frequency and spectrum of sinopulmonary complications among subjects with primary immunodeficiency disorders. METHODS: The subjects included all patients with primary immunodeficiency who were registered prospectively between January 2004 and December 2013 in the Kuwait National Primary Immunodeficiency Disorders Registry. RESULTS: A total of 202 subjects were registered during the study period. Subjects with combined immunodeficiencies were the most prevalent (65 subjects, 32.1%), followed by well-defined syndromes with immunodeficiency (45 subjects, 22.2%) and predominantly antibody deficiencies (35 subjects, 17.3%). A total of 295 sinopulmonary manifestations were observed in 127 subjects (63%); 157 manifestations (53.2%) were observed among the presenting symptoms, and 138 manifestations (46.8%) occurred after establishment of the primary immunodeficiency disorder diagnosis. Sinopulmonary manifestations were more common in subjects with predominantly antibody deficiencies (2.3 manifestations/subject), followed by subjects with combined immunodeficiencies (1.75 manifestations/subject). Pneumonia was the most common manifestation (108 episodes affecting 80 subjects), followed by otitis media (81 episodes affecting 59 subjects), bronchiectasis in 28 subjects (13.8%), and asthma in 22 subjects (11%). Microbial organisms were isolated during 46 episodes of pneumonia (42.5%) (cytomegalovirus and Pneumocystis jirovecii were the most common). There were 57 deaths (28%) during the study period. Twenty-four deaths (42%) were due to pulmonary complications as follows: pneumonia (16 subjects, 8%), pulmonary hemorrhage (6 subjects, 3%), and aspiration pneumonia (2 subjects, 1%). CONCLUSIONS: Sinopulmonary complications are common in subjects with primary immunodeficiency. They can be serious and continue to occur even after proper treatment is initiated. The pulmonologist should play an important role in the management of subjects with primary immunodeficiency disorder.

show abstract

“…Эра активного изучения ПИД началась в 50-60-е годы прошлого столетия, когда появился сам термин и были описаны первые варианты ПИД [6], расшиф-рованы некоторые механизмы их патогенеза [7], по-ложено начало заместительной терапии внутривен-ными иммуноглобулинами (ВВИГ) [8] и проведена первая трансплантация стволовых клеток [9].…”

unclassified